Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

NCT00003472 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Oligodendroglioma, Adult

Interventions

DRUG: Antineoplaston therapy (Atengenal + Astugenal)

Sponsor

Burzynski Research Institute